Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elelyso for Bone Involvement in Gaucher Disease
NCT04353466Completed
- Sponsor
- Shaare Zedek Medical Center
- Start
- Jan 2017
- Primary completion
- Jul 2021
- Modality
- Replacement Enzymes
01
Overview
Open-label, single-arm trial of taliglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Shaare Zedek Medical Center. Primary endpoint: Quantitative Chemical Shift Imaging Fat Fraction at 12 months. Started Jan 2017; status: completed.
02
Drugs
taliglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NCT04353466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353466.